OSSIO
Brennan Marilla has a diverse work experience spanning several industries. Brennan began their career as a Sales Representative at E&J Gallo Winery, where they quickly moved up to the role of District Sales Manager. Following this, they worked as a Medical Sales Representative at Novartis.
In 1994, Marilla joined AngioDynamics, initially as a Sales Representative and later as a Regional Sales Manager. Brennan then transitioned to Medtronic, where they held various roles including Endovascular Sales Representative, South East Regional Endovascular Sales Manager, Sr Product Manager for AAA Stent Grafts, Director of Global Product Management- Endovascular, Global Director of Marketing- Endovascular, and Vice President of US Sales-Endovascular.
Marilla's next position was with Covidien, where they acted as Vice President, Sales & Global Marketing-Venous Vascular, Vice President, Sales & Global Marketing-Peripheral Vascular, and Vice President & General Manager, Endovascular.
After Covidien, Marilla took on the role of Chief Commercial Officer at Surgical Specialties Corporation. During their time there, the company was acquired by an investor syndicate.
Their most recent position has been as the Chief Commercial and Operating Officer at OSSIO, Ltd., an orthopedic start-up focused on creating a more biologically friendly approach to orthopedic fixation.
Overall, Marilla has demonstrated expertise in sales, marketing, commercial operations, and business development. Brennan has worked in both early-stage start-ups and established companies, and has successfully led turnarounds and acquisitions in the medical device industry.
Brennan Marilla attended North Carolina State University from 1986 to 1990, where they obtained a Bachelor of Science (BS) degree in Business Management.
This person is not in any offices
OSSIO
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.